Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: A process for removing .beta.-hydroxy groups from .beta.-hydroxy-containing compounds is disclosed. The process involves the use of a retro-aldol-promoting reagent selected from the group of trimethylamine-N-oxide, triethylamine-N-oxide, trimethylamine-N-oxide-hydrate, and trimethylamine-hydrate and requires dissolution of the substrate in an aprotic solvent and reaction under elevated temperatures. The process is broadly applicable to a variety of substrates including complex cyclic peptides, linear peptides, and non-peptides.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein R', R", R.sup.x1, R.sup.x2, R.sup.y1 -R.sup.y4, R.sup.z1, R.sup.z2, a, b, c, d, e, R.sup.0, R.sup.1 and R.sup.2 are defined as in the specification.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein: R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --;R" and R'" are independently methyl or hydrogen;R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, and R.sup.y4 are independently hydroxy or hydrogen;R.sub.0 is a group of the formula ##STR2## R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, phenyl, p-halo-phenyl, p-nitrophenyl, phenoxy, benzyl, p-halo-benzyl, or p-nitro-benzyl; andR.sub.2 is an acyl side chain as defined herein.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein: R.sup.z1 is hydrogen, --CH.sub.2 OH, --CHOHCH.sub.3 or --CHOHCH.sub.2 C(O)NH.sub.2 ;R.sup.z2 is hydrogen, --CH.sub.2 OH or --CHOHCH.sub.3 ;R.sup.z3 is hydrogen or methyl;R.sup.x1 is hydrogen, hydroxy or O--R.sup.x1' ;R.sup.x1' is C.sub.1 -C.sub.6 alkyl, benzyl, --(CH.sub.2).sub.2 Si(CH.sub.3).sub.3, --CH.sub.2 CH.dbd.CH.sub.2, --CH.sub.2 CHOHCH.sub.2 OH, --(CH.sub.2).sub.a COOH, --(CH.sub.2).sub.b NR.sup.w1 R.sup.w2, --(CH.sub.2).sub.c POR.sup.w3 R.sup.w4 or --[(CH.sub.2).sub.2 O].sub.d --(C.sub.1 -C.sub.6)alkyl;a, b and c are independently 1, 2, 3, 4, 5 or 6;R.sup.w1 and R.sup.w2 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, or R.sup.w1 and R.sup.w2 combine to form --CH.sub.2 (CH.sub.2).sub.e CH.sub.2 --;R.sup.w3 and R.sup.w4 are independently hydroxy, or C.sub.1 -C.sub.6 alkoxy;d is 1 or 2;e is 1, 2 or 3;R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3 and R.sup.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## where: R', R", R'", R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, R.sup.y4, and R.sup.0 are as defined hereinabove; andR.sup.2 is ##STR2## R.sup.3 is ##STR3## R.sup.3a is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy; R.sup.3b and R.sup.3c are independently phenyl or naphthyl;R.sup.3d is C.sub.1 -C.sub.12 alkyl, C.sub.1 -C.sub.12 alkoxy or --O --(CH.sub.2).sub.m -[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl);m is 2, 3 or 4;n is 2, 3 or 4;p is 0 or 1;or a pharmaceutically acceptable salt thereof.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## wherein: R', R", R'", R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, R.sup.y4 and R.sup.0 are as defined hereinabove; andR.sup.2 is ##STR2## R.sup.3 is ##STR3## R.sup.3a, R.sup.3b, R.sup.3c and R.sup.3d are independently hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkynyl, C.sub.1 -C.sub.12 alkoxy, C.sub.1 -C.sub.12 alkylthio, halo, or --O--(CH.sub.2).sub.m --[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl) or --O--(CH.sub.2).sub.q --X--R.sup.4 ;m is 2, 3 or 4;n is 2, 3 or 4;p is 0 or 1;q is 2, 3 or 4;X is pyrrolidino, piperidino or piperazino; andR.sup.4 is hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.3 -C.sub.12 cycloalkyl, benzyl or C.sub.3 -C.sub.12 cycloalkylmethyl;or a pharmaceutically acceptable salt thereof.

Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Abstract: A security and surveillance system having a central monitoring station connected to a plurality of remote installations or subscribers by a transmission medium having a finite bandwidth. Each remote installation includes a plurality of surveillance equipment, including video, audio, and alarm signals, associated with a plurality of monitored locations. The security information collected by the surveillance equipment is serially sampled by a switcher which provides that information to an interface unit transmitter. The interface unit transmitter compresses the video information and decodes the alarm information and then using a key frequency and single side band modulation techniques modulates and sub-channelizes the processed security information into a frequency spectrum. The sub-channelized security information is translated in frequency and transmitted on the transmission medium.